Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank","authors":"Daniel D. Shapiro ,&nbsp;Edwin Jason Abel ,&nbsp;Laurence Albiges ,&nbsp;Dena Battle ,&nbsp;Stephanie A. Berg ,&nbsp;Matthew T. Campbell ,&nbsp;David Cella ,&nbsp;Katie Coleman ,&nbsp;Benjamin Garmezy ,&nbsp;Daniel M. Geynisman ,&nbsp;Tasha Hall ,&nbsp;Elizabeth P. Henske ,&nbsp;Eric Jonasch ,&nbsp;Jose A. Karam ,&nbsp;Salvatore La Rosa ,&nbsp;Bradley C. Leibovich ,&nbsp;Jodi K. Maranchie ,&nbsp;Viraj A. Master ,&nbsp;Benjamin L. Maughan ,&nbsp;Bradley A. McGregor ,&nbsp;Maria I. Carlo","doi":"10.1016/j.urolonc.2025.07.020","DOIUrl":"10.1016/j.urolonc.2025.07.020","url":null,"abstract":"<div><div>Accurate prognostication and personalized treatment selection remain major challenges in kidney cancer. This consensus initiative aimed to provide actionable expert guidance on the development and clinical integration of prognostic and predictive biomarkers and risk stratification tools to improve patient care and guide future research. A modified Delphi method was employed to develop consensus statements among a multidisciplinary panel of experts in urologic oncology, medical oncology, radiation oncology, pathology, molecular biology, radiology, outcomes research, biostatistics, industry, and patient advocacy. Over 3 rounds, including an in-person meeting 20 initial statements were evaluated, refined, and voted on. Consensus was defined <em>a priori</em> as a median Likert score ≥8. Nineteen final consensus statements were endorsed. These span key domains including biomarker prioritization (favoring prognostic biomarkers), rigorous methodology for subgroup and predictive analyses, the development of multi-institutional prospective registries, incorporation of biomarkers in trial design, and improvements in data/biospecimen access. The panel also identified high-priority biomarker types (e.g., AI-based image analysis, ctDNA) for future research. This is the first consensus statement specifically focused on biomarker and risk model development for kidney cancer using a structured Delphi process. The recommendations emphasize the need for rigorous methodology, collaborative infrastructure, prospective data collection, and focus on clinically translatable biomarkers. The resulting framework is intended to guide researchers, cooperative groups, and stakeholders in advancing personalized care for patients with kidney cancer.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 11","pages":"Pages 639-653"},"PeriodicalIF":2.3,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144875328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of genetic evaluation in patients with kidney cancer who meet guidelines for genetic referral","authors":"Elizaveta Makarova M.D. ,&nbsp;Katrina Bakhl ,&nbsp;Seyma Demirsoy Ph.D. ,&nbsp;Kevin Xu M.D. ,&nbsp;Grace Ryu ,&nbsp;Jay D. Raman M.D. ,&nbsp;Maria Baker Ph.D. ,&nbsp;Hong Truong M.D.","doi":"10.1016/j.urolonc.2025.06.009","DOIUrl":"10.1016/j.urolonc.2025.06.009","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the prevalence of genetic counseling and germline genetic testing among patients diagnosed with kidney cancer (KCa) who meet national guidelines for genetic evaluation.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective chart review of adult patients treated between 2017 and 2022 with early onset (diagnosis at ≤ 46 years) or bilateral renal cell carcinoma. Electronic medical records were reviewed to determine rates of referral for genetic services, completion of genetic counseling, and germline genetic testing.</div></div><div><h3>Results</h3><div>Of the 123 patients who met criteria for genetic evaluation, 42 (34%) were referred to genetic counseling, 32 (26%) completed genetic counseling, and 27 (22%) underwent germline testing. Of the 24 patients with available test results, 7 (29%) had pathogenic or likely pathogenic variants, including 2 (8%) with variants in genes associated with renal cell carcinoma.</div></div><div><h3>Conclusion</h3><div>Despite current guidelines recommending genetic counseling for all patients with early-onset or bilateral KCa, referral rates remain low, with only one-third of eligible patients receiving a referral. However, once referred, most patients completed counseling and testing. These findings underscore a critical gap in the implementation of genetic evaluation guidelines and highlight opportunities to improve access and streamline referral pathways for patients with KCa.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 11","pages":"Pages 663.e11-663.e15"},"PeriodicalIF":2.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate-specific antigen screening among transgender women in clinical care: A retrospective chart review study","authors":"Ashley Lacombe-Duncan ,&nbsp;Gabi Celia Ortiz ,&nbsp;Angela Underhill ,&nbsp;Monica Brundage ,&nbsp;Adrien Saucier ,&nbsp;John Goodhew ,&nbsp;Quang Nguyen ,&nbsp;Mona Loutfy","doi":"10.1016/j.urolonc.2025.07.017","DOIUrl":"10.1016/j.urolonc.2025.07.017","url":null,"abstract":"<div><h3>Background</h3><div>Prostate-specific antigen (PSA) screening is controversial due to over-detection and treatment of low-grade prostate cancer. Consequently, the Canadian Urological Association (CUA) and the Canadian Task Force on Preventive Health Care (CTFPHC) differ with respect to recommending for versus recommending against PSA screening. Regardless, Canadian and global guidelines recommending PSA screening fail to address transgender (trans) women/transfeminine persons, though studies suggest this population remains at risk of prostate cancer, particularly those who have not accessed gender-affirming hormone therapy (GAHT) or gender-affirming surgeries. The objectives of this study were to: (1) characterize the prevalence of trans women/transfeminine persons aged 50+ who have ever received PSA screening and (2) explore sociodemographic, clinical, and social/structural factors associated with ever receiving PSA screening.</div></div><div><h3>Methods</h3><div>Drawing on a sub-sample of retrospective chart review data from trans women/ transfeminine persons aged 50+ across 6 family medicine and/or HIV clinics in Montreal and Toronto, Canada, 2018 to 2019 (excluding 1 endocrinology-only clinic), we assessed the prevalence of having received PSA screening (ever vs. never). Then, we compared ever having received PSA screening across sociodemographic (e.g., age), clinical (e.g., feminizing hormone therapy use), and social/structural factors (e.g., employment) using bivariable and multivariable binary logistic regression analyses.</div></div><div><h3>Results</h3><div>Among trans women/transfeminine persons aged 50+ (<em>n</em> <em>=</em> 213), 23.0% had ever received PSA screening (95% CI: 17.5%–29.3%). Applying logistic regression, being HIV positive (compared to being HIV negative) was statistically significantly associated with ever having received PSA screening in both bivariable (OR: 3.0, 95% CI: 1.10, 8.19, <em>P</em> <em>&lt;</em> 0.05) and multivariable analyses controlling for age (OR: 3.61, 95% CI: 1.28, 10.19, <em>P</em> <em>&lt;</em> 0.05). Compared to not having had vaginoplasty and controlling for age, having had vaginoplasty trended towards lower odds of ever having received PSA screening (OR: 0.43, 95% CI: 0.17, 1.06, <em>P</em> <em>=</em> 0.066).</div></div><div><h3>Conclusions</h3><div>Findings suggest that most trans women/transfeminine persons aged 50+ in our sample had never received PSA screening. Future studies could explore trans women/transfeminine person patient-provider decision-making with respect to PSA screening. Findings reinforce the need for continued discussion of trans women/transfeminine persons’ risk of prostate cancer, particularly given inconclusive research evidence to suggest otherwise for those not taking GAHT and call for clarity in PSA screening guidelines for this population to promote health equity.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 11","pages":"Pages 664.e1-664.e9"},"PeriodicalIF":2.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of radical nephroureterectomy and kidney-sparing surgery in the treatment of high-grade upper tract urothelial carcinoma","authors":"Kyle Moore M.D. ,&nbsp;Helen Gao B.A. ,&nbsp;Benjamin Lichtbroun M.D. ,&nbsp;Jennifer Delgado B.A. ,&nbsp;Anirudh Kulkarni B.S. ,&nbsp;Kevin Chua M.D. ,&nbsp;John Pfail M.D. ,&nbsp;Arnav Srivastava M.D., M.P.H. ,&nbsp;David Golombos M.D. ,&nbsp;Thomas Jang M.D. ,&nbsp;Vignesh T. Packiam M.D. ,&nbsp;Saum Ghodoussipour M.D.","doi":"10.1016/j.urolonc.2025.06.023","DOIUrl":"10.1016/j.urolonc.2025.06.023","url":null,"abstract":"<div><h3>Purpose</h3><div>Upper tract urothelial carcinoma (UTUC) can be managed via radical nephroureterectomy or kidney-sparing surgery. Unfortunately, there is a paucity of data comparing radical vs. kidney-sparing management for high-grade UTUC. This study compares outcomes of radical nephroureterectomy to kidney-sparing surgery for high-grade UTUC.</div></div><div><h3>Materials and methods</h3><div>We retrospectively reviewed all patients with &gt; 1-year follow-up treated for high-grade UTUC at our institution from 2015 to 2021. Oncologic and clinical outcomes were recorded. Procedure-related burden was analyzed as total procedures under anesthesia, anesthesia time, days hospitalized, and estimated cost of care.</div></div><div><h3>Results</h3><div>We identified 47 patients treated with radical nephroureterectomy and 16 with kidney-sparing surgery, including 1 managed via segmental ureterectomy, 14 with ureteroscopy and ablation, and 1 percutaneously. Survival outcomes, including 5-year overall survival, 3-year metastasis-free survival, and 3-year recurrence-free survival, were similar between cohorts. Patients managed with radical nephroureterectomy experienced fewer procedures but more severe perioperative complications than those treated with kidney-sparing surgery –2.1 ± 1.7 procedures vs. 3.3 ± 1.8 procedures (<em>P</em> = 0.037) and 0.4 ± 0.6 vs. 0 severe complications per patient, respectively (<em>P</em> = 0.047). Total anesthesia time and days hospitalized for radical nephroureterectomy were similar to kidney-sparing surgery at 477 ± 184 minutes vs. 377 ± 216 minutes (<em>P</em> = 0.13) and 6.7 ± 4.5 days vs. 5.5 ± 4.6 days, respectively (<em>P</em> = 0.36). Patients treated with radical nephroureterectomy experienced a greater median in-network cost of care than kidney-sparing surgery at $9,257 (IQR $7,386–$12,550) vs. $5,789 (IQR $4,833–$7,069), respectively (<em>P</em> = 0.009). Average changes in GFR were −21.1 mL/min/1.73 m² and -6.8 mL/min/1.73 m² for radical nephroureterectomy and kidney-sparing surgery, respectively (<em>P</em> = 0.11). At 2 years after surgery, 97.1% of patients who underwent radical nephroureterectomy and 100.0% who underwent kidney-sparing surgery experienced a GFR decline &lt; 10 mL/min/1.73 m² (<em>P</em> = 0.12).</div></div><div><h3>Conclusion</h3><div>Oncologic and clinical outcomes were similar in this select cohort of patients with high-grade UTUC treated with kidney-sparing surgery or radical nephroureterectomy. Patients treated with kidney-sparing surgery endured a greater procedural load than radical nephroureterectomy but at reduced in-network cost and with fewer severe complications. Larger datasets are needed to further evaluate outcomes and treatment burdens of radical nephroureterectomy vs. kidney-sparing surgery as high-grade UTUC treatment.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 11","pages":"Pages 661.e19-661.e28"},"PeriodicalIF":2.3,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benign ureteroenteric anastomotic stricture predictors in radical cystectomy patients: A critical analysis focusing on the nutritional risk index and postoperative urinary tract infection","authors":"Sinharib Citgez M.D. ,&nbsp;Emre Bulbul M.D. ,&nbsp;Sami Berk Ozden M.D. ,&nbsp;Fahri Yavuz Ilki M.D. ,&nbsp;Fatih Yildiz M.D. ,&nbsp;Ahmet Vural M.D. ,&nbsp;Cetin Demirdag M.D.","doi":"10.1016/j.urolonc.2025.07.011","DOIUrl":"10.1016/j.urolonc.2025.07.011","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate preoperative, surgery-related, and postoperative parameters in terms of their ability to predict benign ureteroenteric anastomotic strictures (UAS) after radical cystectomy (RC).</div></div><div><h3>Methods</h3><div>The clinical data of patients who underwent RC between January 2016 and December 2022 at a tertiary referral center were retrospectively collected. A total of 79 RC patients who met the inclusion criteria were included in the study. The patients were divided into 2 groups during postoperative follow-up: those who developed UAS and those who did not develop UAS.</div></div><div><h3>Results</h3><div>UAS developed in 20 (25.3%) patients after RC, while 59 (74.7%) patients did not develop UAS. The median follow-up times of the UAS and non-UAS groups were 38 (interquartile range: 12–69) and 35 (12–64) months, respectively (<em>P</em> = 0.242). The mean Nutritional Risk Index (NRI) scores of the UAS and non-UAS groups were 79±9.8 and 89.8 ± 13.8, respectively (<em>P</em> = 0.002). Multivariate analysis identified several independent predictors of UAS. The presence of an American Society of Anesthesiologists (ASA) IV classification (<em>P</em> &lt; 0.001), preoperative hydronephrosis (<em>P</em> = 0.039), NRI score (<em>P</em> = 0.019), and postoperative urinary tract infection (UTI) (<em>P</em> = 0.016) were significant predictors of postoperative UAS. The optimal cut-off value of the NRI was determined to be 83.05, with an area under the curve of 0.731 at this cut-off.</div></div><div><h3>Conclusions</h3><div>Postoperative UTI, presence of ASA IV, and preoperative hydronephrosis were identified as independent risk factors for UAS development after RC. The NRI score was lower in patients with UAS than in those without UAS. Poor nutritional status in patients undergoing RC may contribute to an increased risk of UAS development.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 11","pages":"Pages 660.e15-660.e22"},"PeriodicalIF":2.3,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of prophylactic incisional negative pressure wound therapy on surgical site infection following open radical cystectomy","authors":"Daniel S. Roberson ,&nbsp;Matthew T. McLeay II ,&nbsp;Grant Henning ,&nbsp;Gianni Morales-Martinez ,&nbsp;Prabin Thapa ,&nbsp;Abhinav Khanna ,&nbsp;Igor Frank ,&nbsp;Matthew K. Tollefson ,&nbsp;Paras Shah ,&nbsp;R. Jeffrey Karnes ,&nbsp;Stephen A. Boorjian ,&nbsp;Vidit Sharma","doi":"10.1016/j.urolonc.2025.07.010","DOIUrl":"10.1016/j.urolonc.2025.07.010","url":null,"abstract":"<div><h3>Purpose</h3><div>Surgical site infection (SSI) following open radical cystectomy (ORC) is common and carries significant morbidity. Incisional negative pressure wound therapy (iNPWT) has not been rigorously studied in this population. Herein, we evaluate the association between prophylactic iNPWT and postoperative wound complications in ORC patients.</div></div><div><h3>Materials and Methods</h3><div>We queried our institutional, prospectively maintained cystectomy registry for patients who underwent ORC between 2000 and 2023, and stratified patients by receipt of prophylactic iNPWT. The primary outcome was SSI incidence within 90-days following surgery. Secondary outcomes included 90-day wound dehiscence, symptomatic seroma, and a composite endpoint of any of those 3 wound events. Multivariable logistic regression models adjusted for patient characteristics.</div></div><div><h3>Results</h3><div>Among 2,375 patients who underwent ORC, 124(5.2%) received prophylactic iNPWT. Patients who received iNPWT had higher rates of SSI risk factors: median BMI (31 vs. 28, <em>P</em> &lt; 0.01), diabetes (28% vs. 18%, <em>P</em> = 0.01), and ileal conduit diversion (86% vs. 71%, <em>P</em> &lt; 0.01). On unadjusted analyses, SSI incidence was 6.5% and 10.4% for the iNPWT and non-iNPWT cohorts, respectively. After adjusting for baseline characteristics, prophylactic iNPWT was associated with a significantly lower odds of SSI (OR 0.47, 95%CI 0.22–0.99, <em>P</em> = 0.048). No significant associations were observed between iNPWT utilization and secondary outcomes.</div></div><div><h3>Conclusions</h3><div>Prophylactic iNPWT therapy is associated with a reduced risk of SSI following ORC. While prospective and randomized corroboration is warranted, these data support the incorporation of this low-cost intervention into postoperative pathways for high-risk ORC patients.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 10","pages":"Pages 586-593"},"PeriodicalIF":2.3,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144837928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction required for article titled “Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma”","authors":"Hong-Lin Zhong","doi":"10.1016/j.urolonc.2024.08.013","DOIUrl":"10.1016/j.urolonc.2024.08.013","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 9","pages":"Page 529"},"PeriodicalIF":2.3,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover 2 - Masthead","authors":"","doi":"10.1016/S1078-1439(25)00295-9","DOIUrl":"10.1016/S1078-1439(25)00295-9","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 9","pages":"Page IFC"},"PeriodicalIF":2.3,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: A single-center real-world study.","authors":"Yi-Chieh Chen, Jiun-I Lai, Yen-Hwa Chang, Hsiao-Jen Chung, Tzu-Ping Lin, Yi-Hsiu Huang, Tzu-Chun Wei, Ming-Huang Chen, Chueh-Chuan Yen, Peter Mu-Hsin Chang","doi":"10.1016/j.urolonc.2025.07.014","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.07.014","url":null,"abstract":"<p><strong>Background: </strong>Upper tract urothelial carcinoma (UTUC) is more common in Taiwan than in other regions. Although adjuvant nivolumab showed efficacy in high-risk urothelial carcinoma in the CheckMate 274 trial, its benefit in UTUC remains unclear. In this study, the real-world effectiveness and safety of adjuvant nivolumab were evaluated in Taiwanese patients with UC.</p><p><strong>Methods: </strong>This retrospective, single-center study included 42 patients with UC who underwent radical resection and received adjuvant nivolumab at Taipei Veterans General Hospital. Survival outcomes were analyzed using the Kaplan-Meier method and Cox regression.</p><p><strong>Results: </strong>The cohort had a median age of 70.5 years, and 54.8% of enrollees were male. UTUC accounted for 85.7% of all cases. The median follow-up was 17.3 months, and 26.2% of patients experienced recurrence or died during their follow-up. At 6, 12, and 24 months, the DFS rate was 89.9%, 78.0%, and 68.4%, respectively. The favorable 24-month DFS was more favorable in patients with UTUC (73.1%) vs. those with bladder UC (66.7%). PD-L1 expression ≥1% was associated with a nonsignificant DFS benefit (hazard ratio = 0.50, P = 0.272). Adjuvant nivolumab was well tolerated, with 40.5% of patients experiencing largely mild treatment-related adverse events.</p><p><strong>Conclusion: </strong>Adjuvant nivolumab was effective and well tolerated in Taiwanese patients with UTUC, resulting in promising DFS and OS. These findings suggest potential benefits of nivolumab in patients with UTUC. Further research on genomic and environmental influences and a prospective validation to refine patient selection for adjuvant immunotherapy are needed.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy testing in urological cancers: Focus on urine","authors":"Pasquale Pisapia M.D., Ph.D. ,&nbsp;Francesco Pepe Ph.D. ,&nbsp;Gianluca Russo Ph.D. ,&nbsp;Raffaele Capoluongo M.D., Ph.D. ,&nbsp;Mariano Coppola M.D., Ph.D. ,&nbsp;Francesco Del Giudice M.D., Ph.D. ,&nbsp;Matteo Ferro M.D., Ph.D. ,&nbsp;Antonio Madonna M.D., Ph.D. ,&nbsp;Michele Musone M.D., Ph.D. ,&nbsp;Giancarlo Troncone M.D., Ph.D. ,&nbsp;Umberto Malapelle Ph.D. ,&nbsp;Felice Crocetto M.D., Ph.D.","doi":"10.1016/j.urolonc.2025.07.034","DOIUrl":"10.1016/j.urolonc.2025.07.034","url":null,"abstract":"<div><div>Liquid biopsy has significantly transformed the management of patients with urological cancers. In particular, alternative sources of tumor nucleic acids and analytes beyond blood have taken on a crucial role in these malignancies. In this context, urine represents a valuable alternative to blood and should be considered within an expanded concept of liquid biopsy. Urine acts as a natural ultracentrifuge of blood, making it a complementary molecular resource alongside plasma. This review aims to summarize the potential applications of urine biomarker analysis in the management of urological malignancies, highlighting current challenges and future perspectives for integrating liquid biopsy into clinical practice.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 10","pages":"Pages 553-564"},"PeriodicalIF":2.3,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}